Pheochromocytoma and Sweating

A rare cause with a memorable symptom pattern

Pheochromocytomas are neuroendocrine tumours of the chromaffin cells that produce excess epinephrine and norepinephrine. Estimated incidence is roughly 0.6 to 0.8 cases per 100,000 people per year, and the tumours are found in an estimated 0.2 to 0.6% of patients with hypertension. Because the tumour releases catecholamines in bursts, symptoms are typically paroxysmal: episodes of headache, palpitations, sweating, pallor or anxiety, often with a spike in blood pressure. Episodes may last minutes to hours and can be triggered by exercise, positional change, certain foods or medications.

The sweating here is a sympathoadrenal response to a surge of circulating catecholamines. It is generalized (rather than confined to palms or underarms) and usually episodic rather than continuous, which distinguishes it from primary focal hyperhidrosis. When it is unexplained sweating in an adult, it is one of the reasons a clinician may consider ordering plasma or urinary metanephrines.

A 2016 systematic review pooled sensitivity estimates for the individual symptoms of pheochromocytoma across published series. Headache, palpitations and sweating are the three most consistent, and each appears in roughly half to two-thirds of patients. The complete triad is far less common.

The "classic triad" of headache, palpitations and sweating is the most memorable clinical picture, but modern cohorts show that only a minority of patients present with all three at once. That is one reason why biochemical testing is central to the diagnosis rather than symptom clusters.

What pheochromocytoma-related sweating looks like

The sweating that accompanies pheochromocytoma is usually generalized and episodic: it comes on with the same paroxysm that produces the headache, palpitations, tremor, pallor and blood-pressure spike, and it subsides between episodes. That episodic, whole-body pattern, together with other adrenergic features, is what distinguishes it from primary focal hyperhidrosis (which is limited to the palms, soles, underarms or face and does not come with cardiovascular symptoms).

Because pheochromocytoma is rare, sweating is nearly always caused by something else. Clinicians usually consider it only when other features raise suspicion: resistant or paroxysmal hypertension, symptom spells triggered by anaesthesia, food or drugs, an adrenal mass found incidentally on imaging, or a family history of related tumour syndromes (such as MEN2, von Hippel–Lindau, or neurofibromatosis type 1).

How the diagnosis is made

Guideline-directed testing rests on measuring plasma free metanephrines or 24-hour urinary fractionated metanephrines, which are the breakdown products of the tumour's catecholamines. Plasma free metanephrines have a reported sensitivity around 97% and specificity around 93% in the landmark 2002 JAMA multicentre study by Lenders and colleagues. Imaging (CT or MRI, sometimes functional imaging such as MIBG or DOTATATE PET) is used to locate the tumour once biochemistry is positive.

Symptom pattern alone cannot make or exclude the diagnosis. Sweating is a very non-specific symptom and pheochromocytoma is a very uncommon cause of it. This page describes an association reported in observational and clinical studies; it is not a screening tool and it is not a diagnosis for any individual.

What this means in plain terms

The classical picture is well known, but the numbers show two things at once. First, sweating really is one of the three most consistent symptoms: about half of patients with pheochromocytoma have diaphoresis. Second, only a minority ever show the full headache-palpitations-sweating triad, so its absence proves little. Any evaluation of unexplained, episodic sweating with adrenergic features (racing heart, headache, blood-pressure changes, pallor, weight loss) is a clinical task, involving blood or urine tests and, if indicated, imaging. Because the tumour is treatable when found, that evaluation is worth doing when it is indicated, but assumptions cannot be made from symptoms alone.

Methodology and limitations

This page draws on a peer-reviewed systematic review of the diagnostic value of clinical signs and symptoms in pheochromocytoma (Soltani 2016), a case-focused literature review of diaphoresis in pheochromocytoma (Warren 2022), a single-centre cohort of 94 patients (Falhammar 2018), and a population-based/incidence review (Frontiers in Endocrinology 2022). Diagnostic testing figures come from the landmark plasma metanephrines study (Lenders et al., JAMA 2002).

Limitations: pooled sensitivities come from heterogeneous studies with variable definitions and referral biases, and confidence intervals are wide (e.g. the classic-triad estimate spans 28.6–84.7%). Modern series include more incidentally detected tumours, which tend to have fewer symptoms and shift reported frequencies. Sweating is highly non-specific and is almost never caused by pheochromocytoma in the general population. This page is general education, not a diagnosis or medical advice; a clinician can determine whether biochemical testing is warranted.

Frequently asked questions

Is sweating a symptom of pheochromocytoma?

Yes. It is one of the three classical features, alongside headache and palpitations. Pooled data from 28 studies put diaphoresis sensitivity at 52.4% (95% CI 45.7–59.1). It is typically generalized and episodic, tied to catecholamine surges from the tumour.

How often does the full classic triad occur?

Only in about a quarter of patients. Modern reviews estimate the complete triad of headache, palpitations and sweating in roughly 25% of cases (17% in one 94-patient Swedish cohort). Its absence does not exclude the tumour.

How rare is pheochromocytoma?

Very rare: estimated incidence about 0.6 to 0.8 cases per 100,000 people per year. Among patients with hypertension, roughly 0.2 to 0.6% are found to have a pheochromocytoma, so it is uncommon but important.

Could my sweating be a pheochromocytoma?

Almost always no. Sweating is a very non-specific symptom with many common causes. Pheochromocytoma is usually considered only when sweating comes with paroxysmal high blood pressure, headache, palpitations, pallor or an adrenal mass. A clinician can decide whether biochemical testing is warranted.

How is pheochromocytoma diagnosed?

By measuring the metabolites of the tumour's catecholamines (plasma free metanephrines or 24-hour urinary fractionated metanephrines), with imaging to locate the tumour when results are positive. Symptom pattern alone is not diagnostic.

Does this page mean pheochromocytoma is causing my symptoms?

No. This describes an association from clinical and epidemiological studies. Only a clinician can determine the cause of an individual's sweating after considering the full picture.

Sources

Primary peer-reviewed studies and official sources first, then reviews and institutional framing (secondary).

1. Soltani A, Pourian M, Davani BM. Does this patient have Pheochromocytoma? A systematic review of clinical signs and symptoms. J Diabetes Metab Disord. 2016;15:11. Pooled sensitivity of diaphoresis 52.4% (95% CI 45.7–59.1); triad positive LR ~6.3 in hypertensive patients. Full text
2. Warren HN, et al. Diaphoresis as the Prominent Manifestation of Pheochromocytoma. J Investig Med High Impact Case Rep. 2022. Incidence ~0.6–0.8 per 100,000/year; classic triad in ~25% of cases; diaphoresis in <50%. Full text
3. Falhammar H, Kjellman M, Calissendorff J. Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr Connect. 2018;7(1):186–192. Paroxysmal symptoms 62%; complete classic triad in 17%; sweating among the four commonest symptoms. Full text
4. Lenders JWM, Pacak K, Walther MM, et al. Biochemical diagnosis of pheochromocytoma: which test is best? JAMA. 2002;287(11):1427–1434. Plasma free metanephrines sensitivity ~97%, specificity ~93%. PubMed
5. Neumann HPH, Young WF, Eng C. Pheochromocytoma and paraganglioma. N Engl J Med. 2019;381(6):552–565. Modern reference on epidemiology, genetics and management. (secondary) NEJM

How to cite this page

Related reading on this site

• Hyperhidrosis and thyroid disease: the association
• Diabetes and sweating: hypoglycemia and autonomic neuropathy
• Night sweats in primary care: prevalence and evaluation
• Emotional sweating and the nervous system
• Talking to a clinician about sweating